Drug Cos. Call 'Blocking Patent' Rule An 'Existential Threat'
Several drugmakers and representatives of the drug lobby have urged the U.S. Supreme Court to undo the Federal Circuit's "blocking patent" doctrine, arguing it "poses an existential threat to innovation" in...To view the full article, register now.
Already a subscriber? Click here to view full article